<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00102440</url>
  </required_header>
  <id_info>
    <org_study_id>C02-010</org_study_id>
    <secondary_id>U1111-1114-0184</secondary_id>
    <nct_id>NCT00102440</nct_id>
  </id_info>
  <brief_title>Febuxostat Versus Allopurinol Control Trial in Subjects With Gout</brief_title>
  <acronym>FACT</acronym>
  <official_title>A Phase 3, Randomized, Multicenter Study Comparing the Safety and Efficacy of Oral Febuxostat Versus Allopurinol in Subjects With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily
      (QD), versus allopurinol in subjects with gout.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a randomized, controlled, double-blind study of 52 weeks duration. Subjects
      receiving prior urate-lowering therapy underwent a 2-week washout period prior to
      randomization. Subjects were then randomized to one of three treatment groups: febuxostat 80
      milligram (mg), febuxostat 120 mg, or allopurinol 300 mg. Naproxen (250 mg twice daily) or
      colchicine (0.6 mg once daily) was provided for prophylaxis of acute gout flares during the
      washout period and the first 8 weeks of double-blind treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With the Last 3 Serum Urate Levels &lt;6.0 Milligrams Per Deciliter (mg/dL)</measure>
    <time_frame>Last 3 Visits (up to 52 weeks)</time_frame>
    <description>Each subject's serum urate at the last 3 visits determined the subject's response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 28 Visit</measure>
    <time_frame>Week 28</time_frame>
    <description>Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 28 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 52 Visit</measure>
    <time_frame>Week 52</time_frame>
    <description>Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 52 visit was summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Final Visit</measure>
    <time_frame>Final Visit (up to 52 weeks)</time_frame>
    <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Urate Levels at Week 28.</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Urate Levels at Week 52.</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Urate Levels at Final Visit</measure>
    <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
    <description>The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</measure>
    <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
    <description>Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <description>The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.</measure>
    <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
    <description>Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.</measure>
    <time_frame>Weeks 8 through 52</time_frame>
    <description>The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">760</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 120 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol 300 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
    <arm_group_label>Febuxostat 80 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
    <arm_group_label>Febuxostat 120 mg QD</arm_group_label>
    <other_name>TMX-67</other_name>
    <other_name>Tei-6720</other_name>
    <other_name>Uloric</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.</description>
    <arm_group_label>Allopurinol 300 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meeting the preliminary criteria of the American Rheumatism Association for the
             classification of the acute arthritis of primary gout.

          -  Serum uric acid ≥ 8.0 milligrams per deciliter (mg/dL) at Baseline

        Exclusion Criteria:

          -  Serum creatinine &gt;1.5 mg/dL

          -  Calculated creatinine clearance of &lt;50 milliliters per minutes (mL/min)

          -  Pregnancy or lactation;

          -  Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine,
             thiazide diuretics, or medications containing aspirin (&gt;325 mg) or other salicylates;

          -  Body Mass Index (BMI) &gt;50 kilogram per meter²(kg/m²);

          -  A history of xanthinuria, active liver disease, or hepatic dysfunction;

          -  A history of alcohol abuse or intake of 14 or more alcohol-containing drinks/week.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <link>
    <url>http://www.rheumatology.org/</url>
    <description>American College of Rheumatology</description>
  </link>
  <link>
    <url>http://general.takedapharm.com/content/file.aspx?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&amp;fileTypeCode=ULORICPI</url>
    <description>Uloric Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 8;353(23):2450-61.</citation>
    <PMID>16339094</PMID>
  </results_reference>
  <results_reference>
    <citation>Becker MA, MacDonald PA, Hunt BJ, Lademacher C, Joseph-Ridge N. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):585-91. doi: 10.1080/15257770802136032.</citation>
    <PMID>18600509</PMID>
  </results_reference>
  <results_reference>
    <citation>Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther. 2010 Dec;32(14):2386-97. doi: 10.1016/j.clinthera.2011.01.008.</citation>
    <PMID>21353107</PMID>
  </results_reference>
  <results_reference>
    <citation>Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.</citation>
    <PMID>22052584</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2005</study_first_submitted>
  <study_first_submitted_qc>January 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2005</study_first_posted>
  <results_first_submitted>March 12, 2009</results_first_submitted>
  <results_first_submitted_qc>May 26, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uric Acid</keyword>
  <keyword>xanthine oxidase</keyword>
  <keyword>tophi</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at 112 investigative sites, 106 in the United States and 6 in Canada, from 11 July 2002 to 20 February 2004.</recruitment_details>
      <pre_assignment_details>Subjects currently receiving urate-lowering therapy discontinued those urate-lowering therapies and initiated prophylactic medications before enrollment in once daily (QD) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Allopurinol 300 mg QD</title>
          <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="251"/>
                <participants group_id="P3" count="253"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gout Flare</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reason(s)</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Allopurinol 300 mg QD</title>
          <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="256"/>
            <count group_id="B2" value="251"/>
            <count group_id="B3" value="253"/>
            <count group_id="B4" value="760"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 years to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="11.69"/>
                    <measurement group_id="B2" value="52.0" spread="12.12"/>
                    <measurement group_id="B3" value="51.6" spread="12.63"/>
                    <measurement group_id="B4" value="51.8" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="243"/>
                    <measurement group_id="B4" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18.5 kilogram per meter² (kg/m²)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18.5 kg/m² to &lt;25 kg/m²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 kg/m² to &lt;30 kg/m²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30 kg/m²</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calculated Creatinine Clearance</title>
          <description>Calculated creatinine clearance based on the Cockcroft-Gault equation using ideal body weight.</description>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;50 milliliters per minute (mL/min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 mL/min to &lt;80 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80 mL/min to &lt;120 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥120 mL/min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of Primary Palpable Tophus</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No, but other tophi present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No and no other tophi present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="204"/>
                    <measurement group_id="B4" value="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="193"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="195"/>
                    <measurement group_id="B4" value="587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With the Last 3 Serum Urate Levels &lt;6.0 Milligrams Per Deciliter (mg/dL)</title>
        <description>Each subject’s serum urate at the last 3 visits determined the subject’s response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.</description>
        <time_frame>Last 3 Visits (up to 52 weeks)</time_frame>
        <population>Analysis was performed on the intent-to-treat (ITT) subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With the Last 3 Serum Urate Levels &lt;6.0 Milligrams Per Deciliter (mg/dL)</title>
          <description>Each subject’s serum urate at the last 3 visits determined the subject’s response for the primary efficacy variable. A subject who prematurely discontinued without least 3 postbaseline serum urate levels was considered a nonresponder; if at least 3 serum urate were obtained postbaseline, those 3 visits were used. The last 3 visits used may have differed for each subject.</description>
          <population>Analysis was performed on the intent-to-treat (ITT) subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="250"/>
                <count group_id="O3" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of febuxostat 80 mg to allopurinol was declared if the value of the lower bound of the 97.5% confidence interval is &gt; -10%.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>32</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>23.1</ci_lower_limit>
            <ci_upper_limit>41.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of febuxostat 120 mg to allopurinol was declared if the value of the lower bound of the 97.5% confidence interval is &gt; -10%.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>41</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_lower_limit>31.5</ci_lower_limit>
            <ci_upper_limit>49.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Comparisons of each febuxostat dose to allopurinol were adjusted to control the overall 0.05 level of significance for superiority by using Hochberg's method for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 28 Visit</title>
        <description>Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 28 visit was summarized.</description>
        <time_frame>Week 28</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 28 Visit</title>
          <description>Serum urate values were obtained at the Week 28 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 28 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 52 Visit</title>
        <description>Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 52 visit was summarized.</description>
        <time_frame>Week 52</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Week 52 Visit</title>
          <description>Serum urate values were obtained at the Week 52 visit. The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the Week 52 visit was summarized.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.883</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Final Visit</title>
        <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.</description>
        <time_frame>Final Visit (up to 52 weeks)</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Serum Urate &lt;6.0 mg/dL at Final Visit</title>
          <description>The percentage of subjects whose serum urate was &lt;6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected. The timing of the final visit may have differed for each subject.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Urate Levels at Week 28.</title>
        <description>Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized.</description>
        <time_frame>Baseline and Week 28</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Urate Levels at Week 28.</title>
          <description>Serum urate values were obtained at the Week 28 visit. The percent change in serum urate was calculated as [(week 28 - baseline levels/baseline)]*100 and summarized.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.3" spread="15.76"/>
                    <measurement group_id="O2" value="-53.5" spread="18.20"/>
                    <measurement group_id="O3" value="-34.8" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Urate Levels at Week 52.</title>
        <description>Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Urate Levels at Week 52.</title>
          <description>Serum urate values were obtained at the Week 52 visit. The percent change in serum urate was calculated as [(week 52 - baseline levels/baseline)]*100 and summarized.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47.7" spread="17.50"/>
                    <measurement group_id="O2" value="-53.0" spread="19.31"/>
                    <measurement group_id="O3" value="-34.8" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Urate Levels at Final Visit</title>
        <description>The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.</description>
        <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Urate Levels at Final Visit</title>
          <description>The percent change in serum urate from baseline to the Final visit was calculated as [(Final Visit - baseline levels/baseline)]*100 and summarized. The Final visit was the last visit with a serum urate value. The timing of the final visit may have differed for each subject.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug and who had a baseline serum urate ≥8.0 mg/dL. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.7" spread="19.10"/>
                    <measurement group_id="O2" value="-51.5" spread="19.91"/>
                    <measurement group_id="O3" value="-33.0" spread="15.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values for pairwise comparisons are from contrast within the framework of the one-way ANOVA model with treatment as a factor. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
        <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.</description>
        <time_frame>Baseline and Week 28</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Tophus Size at Week 28, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
          <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 28 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 28 visit, the size was assumed to be zero.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" lower_limit="-66.0" upper_limit="4.1"/>
                    <measurement group_id="O2" value="-49.5" lower_limit="-80.0" upper_limit="-34.9"/>
                    <measurement group_id="O3" value="-28.6" lower_limit="-54.9" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
        <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Tophus Size at Week 52, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
          <description>The percent change from baseline in primary tophus size as determined by physical measurement was calculated as [(Week 52 - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at the Screening Visit. If the primary tophus was no longer palpable at the Week 52 visit, the size was assumed to be zero.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.4" lower_limit="-100" upper_limit="-15.6"/>
                    <measurement group_id="O2" value="-65.5" lower_limit="-85.5" upper_limit="-38.9"/>
                    <measurement group_id="O3" value="-49.7" lower_limit="-96.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.164</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.619</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
        <description>Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
        <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Tophus Size at Final Visit, as Determined by Physical Measurement, in Subjects With a Palpable Primary Tophus at Screening.</title>
          <description>Percent change in primary tophus size was calculated as [(Final Visit - baseline sizes)/baseline]*100 for the subset of subjects with a primary palpable tophus at Screening. If tophus was not palpable at Final visit, the size was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had a palpable primary tophus measured at baseline. Missing data were not imputed.</population>
          <units>percent change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.7" lower_limit="-100" upper_limit="-8.3"/>
                    <measurement group_id="O2" value="-43.8" lower_limit="-83.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="-39.6" lower_limit="-65.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.080</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.372</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.246</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.</title>
        <description>The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.</description>
        <time_frame>Baseline and Week 28</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Number of Tophi at Week 28 in Subjects With Palpable Tophi at Screening.</title>
          <description>The change from baseline at Week 28 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 28 visit, the total count was assumed to be zero.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
          <units>number of tophi</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.320</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.411</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.</title>
        <description>The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Number of Tophi at Week 52 in Subjects With Palpable Tophi at Screening.</title>
          <description>The change from baseline at Week 52 in the total number of tophi per subject was calculated for the subset of subjects with palpable tophi at the Screening Visit. If the tophi were no longer palpable at the Week 52 visit, the total count was assumed to be zero.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
          <units>number of tophi</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.507</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.188</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.</title>
        <description>Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
        <time_frame>Baseline and Final Visit (up to 52 weeks)</time_frame>
        <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Number of Tophi at Final Visit in Subjects With Palpable Tophi at Screening.</title>
          <description>Change in number of tophi/subject calculated for the subset of subjects with palpable tophi at Screening. If the tophi were not palpable at the Final Visit, total count was assumed to be 0. The timing of the final visit may have differed for each subject.</description>
          <population>Analysis was performed on the ITT subjects, which were defined as all randomized subjects who took at least 1 dose of study drug, had a baseline serum urate ≥8.0 mg/dL, and had palpable tophi at baseline. Missing data were not imputed.</population>
          <units>number of tophi</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.657</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.444</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.719</p_value>
            <p_value_desc>P-values for pairwise comparisons are from the Wilcoxon rank-sum test. Statistical significance was determined at the 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.</title>
        <description>The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.</description>
        <time_frame>Weeks 8 through 52</time_frame>
        <population>Analysis was performed on the ITT subjects who had at least one dose of study drug between Weeks 8 and 52.</population>
        <group_list>
          <group group_id="O1">
            <title>Febuxostat 80 mg QD</title>
            <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Febuxostat 120 mg QD</title>
            <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Allopurinol 300 mg QD</title>
            <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Requiring Treatment for Gout Flares Between Weeks 8 and 52.</title>
          <description>The percentage of subjects requiring treatment for a gout flare between Weeks 8 and 52 of the double-blind treatment period was summarized. A subject who reported more than 1 gout flare during this period was counted only once.</description>
          <population>Analysis was performed on the ITT subjects who had at least one dose of study drug between Weeks 8 and 52.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="215"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.266</p_value>
            <p_value_desc>Statistical significance was determined at 0.05 level without adjustment for multiple comparisons.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Febuxostat 80 mg QD</title>
          <description>Febuxostat 80 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Febuxostat 120 mg QD</title>
          <description>Febuxostat 120 mg, orally, once daily for up to 52 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Allopurinol 300 mg QD</title>
          <description>Allopurinol 300 mg, orally, once daily for up to 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders not elsewhere classified (NEC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Heart Failures NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Ischaemic Coronary Artery Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Rate and Rhythm Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmias and Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and Chronic Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Fistulae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcers and Perforation, Site Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Intestinal Ulcers and Perforation NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Peritoneal and Retroperitoneal Haemorrhages</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Umbilical Hernias</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergies to Food, Food Additives, Drugs and Other Chemicals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal and Gastrointestinal Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract and Lung Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Skin Structures and Soft Tissue Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Viral Infections NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chest and Lung Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Site Specific Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Coagulation and Bleeding Analyses</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Related Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and Connective Tissue Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Osteoarthropathies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Spine and Neck Deformities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colonic Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Prostatic Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Testicular Neoplasms Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System Vascular Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Central nervous system Hemorrhages &amp; Cerebrovascular Accidents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Cord and Nerve Root Disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Disturbances in Consciousness NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Encephalopathies NEC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure and Impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Renal Lithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm and Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pneumothorax and Pleural Effusions NEC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Pulmonary Thrombotic and Embolic Conditions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Respiratory Failures (Excluding [Excl] Neonatal)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Embolism and Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="145" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea (Excl Infective)</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Nausea and Vomiting Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema NEC</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza Viral Infections</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract and Lung Infections</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infections</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb Injuries NEC (Including [Incl] Traumatic Amputation)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Non-Site Specific Injuries NEC</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver Function Analyses</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Related Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and Connective Tissue Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache NEC</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="253"/>
              </event>
              <event>
                <sub_title>Neurological Signs and Symptoms NEC</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Signs and Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Hypertensive Disorders NEC</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="251"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="253"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research &amp; Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

